Menu Search
Equities

Kalvista Pharmaceuticals Inc

4XC1:DEU

Kalvista Pharmaceuticals Inc

Actions
  • Price (EUR)10.50
  • Today's Change0.10 / 0.96%
  • Shares traded0.00
  • 1 Year change+34.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Kalvista Pharmaceuticals Inc's net income fell 36.31% from a loss of 92.91m to a larger loss of 126.64m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-78.65%
Return on equity-90.84%
Return on investment-87.52%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Kalvista Pharmaceuticals Inc fell by 24.45m. Cash Flow from Financing totalled 150.71m or -- of revenues. In addition the company used 89.23m for operations while cash used for investing totalled 84.72m.
Cash flow per share-3.55
Price/Cash flow per share--
Book value per share4.01
Tangible book value per share4.01
More ▼

Balance sheet in USDView more

Kalvista Pharmaceuticals Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio8.55
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.